RecruitingPhase IIEN original
Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study
NCT06016387Original on ClinicalTrials.gov ↗
⚠️
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The proposed study will evaluate the safety and efficacy of XRT followed by systemic therapy among patients with HER2+, HER2 mutated and/or HER2-amplified metastatic breast cancer and LMD
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rak piersi z dodatnim/zmutowanym/zamplifikowanym HER2, z przerzutami
- •Potwierdzone przerzuty do opon mózgowo-rdzeniowych (w płynie mózgowo-rdzeniowym lub badaniu obrazowym)
- •Wiek od 18 lat
- •Dobry stan sprawności (ECOG ≤2)
- •Odpowiedni odstęp od wcześniejszego leczenia eksperymentalnego
- •Ustąpienie działań niepożądanych po wcześniejszym leczeniu
- •Prawidłowa funkcja serca, krwi, wątroby i nerek (etap 2)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- February 23, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
The Ottawa Hospital
Ottawa, Canada
Sunnybrook Health Sciences Centre
Toronto, Canada
Trial contact
CLIMB-LMD Project Manager
Dr. Katarzyna Jerzak
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.